Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16009363 | 0.98 | GLA (0.50) | GLASMN1; SMN2KDM4EKEAP1ALDH1A1 | |
| SCHEMBL15332877 | 0.92 | GLA (0.46) | GLASMN1; SMN2KDM4EKEAP1ALDH1A1 | |
| SCHEMBL1446165 | 0.86 | KEAP1 (0.54) | GLASMN1; SMN2KDM4EKEAP1ALDH1A1 | |
| SCHEMBL7291045 | 0.85 | KEAP1 (0.52) | GLASMN1; SMN2KDM4EKEAP1ALDH1A1 | |
| SCHEMBL6764986 | 0.83 | KEAP1 (0.50) | GLASMN1; SMN2KDM4EKEAP1ALDH1A1 | |
| SCHEMBL7381439 | 0.83 | KEAP1 (0.50) | GLASMN1; SMN2KDM4EKEAP1ALDH1A1 | |
| SCHEMBL7291054 | 0.83 | KEAP1 (0.50) | GLASMN1; SMN2KDM4EKEAP1ALDH1A1 | |
| SCHEMBL5530665 | 0.83 | KEAP1 (0.50) | GLASMN1; SMN2KDM4EKEAP1ALDH1A1 | |
| SCHEMBL7294030 | 0.83 | KEAP1 (0.50) | GLASMN1; SMN2KDM4EKEAP1ALDH1A1 | |
| SCHEMBL7283905 | 0.83 | KEAP1 (0.50) | GLASMN1; SMN2KDM4EKEAP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 520 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024204554-A1 | SPIROCYCLIC MORPHINAN DERIVATIVE | 日本ケミファ株式会社 | 2024-10-03 | — | — | WO | claimed |
| CN-111819176-B | 4-azaindole compounds | 百时美施贵宝公司 | 2023-12-15 | — | — | CN | claimed |
| EP-3728252-B1 | 4-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-09 | — | — | EP | claimed |
| EP-3710440-B1 | SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-05 | — | — | EP | claimed |
| CN-110035753-B | 1-phenyl acetonide and use thereof | 帕多瓦大学 | 2022-08-05 | — | — | CN | claimed |
| EP-4013508-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | Bayer Aktiengesellschaft (DE) | 2022-06-22 | — | — | EP | claimed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | claimed |
| EP-3512852-A1 | TRAF 6 INHIBITORS | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2019-07-24 | — | — | EP | claimed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | claimed |
| WO-2018050286-A1 | TRAF 6 INHIBITORS | HELMHOLTZ ZENTRUM MUENCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2018-03-22 | — | — | WO | claimed |
| CN-1406225-A | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GLAXO SMITHKLINE S P A (IT) | 2003-03-26 | — | — | CN | claimed |
| CN-1404479-A | 1, 3-dihydro-2H-indol-2-one derivatives, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2003-03-19 | — | — | CN | claimed |
| JP-2002539201-A | — | — | 2002-11-19 | — | — | JP | claimed |
| EP-1255751-A2 | 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND THEIR USE AS LIGANDS FOR V1B OR V1B AND V1A ARGININE-VASOPRESSIN RECEPTORS | SANOFI-SYNTHELABO (FR) | 2002-11-13 | — | — | EP | claimed |
| EP-1161422-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-12 | — | — | EP | claimed |
| EP-1131295-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | claimed |
| WO-2001055130-A2 | NOVEL 1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND THEIR USE AS LIGANDS FOR V1B AND V1A ARGININE-VASOPRESSIN RECEPTORS | SANOFI-SYNTHELABO (FR) | 2001-08-02 | — | — | WO | claimed |
| WO-2000055144-A1 | AMINE DERIVATIVES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| WO-2000031037-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | claimed |
| CN-1016869-B | Process for preparing 6, 7-diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KK (JP) | 1992-06-03 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | GLA 131/4885SMN1; SMN2 3648/4885KDM4E 2270/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | GLA 131/4885SMN1; SMN2 3648/4885KDM4E 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.